Literature DB >> 7705402

HLA-dependent variations in human immunodeficiency virus Nef protein alter peptide/HLA binding.

I Couillin1, F Connan, B Culmann-Penciolelli, E Gomard, J G Guillet, J Choppin.   

Abstract

In human immunodeficiency virus (HIV) infection, sequence variations within defined cytotoxic T lymphocyte (CTL) epitopes may lead to escape from CTL recognition. In a previous report, we have shown that the variable central region of HIV Nef protein (amino acids 73-144) that contains potential CTL epitopes, can escape the CTL response. We suggested that this non recognition occurs through a variety of mechanisms. In particular, we provided evidence that HIV Nef sequences recovered from HLA-A11-expressing individuals have alterations in the major anchor residues essential for binding of the two Nef epitopes (amino acids 73-82 and 84-92) to the HLA-A11 molecule. Here, we investigate in more detail whether variations in autologous Nef sequences affect HLA binding, leading to CTL escape. Potential epitopes were sought by testing Nef peptides containing the HLA-A11-specific motif or related motifs. We confirmed that only the two previously described epitopes identified in cytolysis tests have optimal reactivity with the HLA-A11 molecule. We then sequenced several viral variants from donors that do not express the HLA-A11 molecule and compared the variability of these epitopes with those obtained from HLA-A11-expressing individuals. One substitution (Leu85) found in the sequences isolated from both populations increase the reactivity of the HLA-A11-restricted epitope 84-92, and might explain the difference in immunogenicity observed between the two HLA-A11-restricted epitopes from HLA-A11+ individuals. In addition, selective variations were only detected in virus isolated from HLA-A11-expressing individuals. Furthermore, examination of the association of variant peptides with the HLA-A11 molecule demonstrated that a single substitution within the minimal epitope could not always completely abrogate HLA binding, suggesting that multiple alterations within a particular epitope may accumulate during disease progression, allowing the virus to escape CTL recognition.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7705402     DOI: 10.1002/eji.1830250315

Source DB:  PubMed          Journal:  Eur J Immunol        ISSN: 0014-2980            Impact factor:   5.532


  7 in total

1.  Selection and accumulation of an HIV-1 escape mutant by three types of HIV-1-specific cytotoxic T lymphocytes recognizing wild-type and/or escape mutant epitopes.

Authors:  Tomohiro Akahoshi; Takayuki Chikata; Yoshiko Tamura; Hiroyuki Gatanaga; Shinichi Oka; Masafumi Takiguchi
Journal:  J Virol       Date:  2011-12-07       Impact factor: 5.103

Review 2.  CD8(+)T-cell-mediated control of HIV-1 and SIV infection.

Authors:  Stephanie A Freel; Kevin O Saunders; Georgia D Tomaras
Journal:  Immunol Res       Date:  2011-04       Impact factor: 2.829

Review 3.  Memory CD8+ T cells in HIV infection.

Authors:  A J McMichael; G Ogg; J Wilson; M Callan; S Hambleton; V Appay; T Kelleher; S Rowland-Jones
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  2000-03-29       Impact factor: 6.237

4.  Selection of virus variants and emergence of virus escape mutants after immunization with an epitope vaccine.

Authors:  L Mortara; F Letourneur; H Gras-Masse; A Venet; J G Guillet; I Bourgault-Villada
Journal:  J Virol       Date:  1998-02       Impact factor: 5.103

5.  Recognition of a subregion of human proinsulin by class I-restricted T cells in type 1 diabetic patients.

Authors:  Andréa Toma; Samy Haddouk; Jean-Paul Briand; Luc Camoin; Hanne Gahery; Francine Connan; Danielle Dubois-Laforgue; Sophie Caillat-Zucman; Jean-Gérard Guillet; Jean-Claude Carel; Sylviane Muller; Jeannine Choppin; Christian Boitard
Journal:  Proc Natl Acad Sci U S A       Date:  2005-07-19       Impact factor: 11.205

6.  Different abilities of escape mutant-specific cytotoxic T cells to suppress replication of escape mutant and wild-type human immunodeficiency virus type 1 in new hosts.

Authors:  Mamoru Fujiwara; Junko Tanuma; Hirokazu Koizumi; Yuka Kawashima; Kazutaka Honda; Saori Mastuoka-Aizawa; Sachi Dohki; Shinichi Oka; Masafumi Takiguchi
Journal:  J Virol       Date:  2007-10-24       Impact factor: 5.103

7.  Tumor escape from immune recognition: lethal recurrent melanoma in a patient associated with downregulation of the peptide transporter protein TAP-1 and loss of expression of the immunodominant MART-1/Melan-A antigen.

Authors:  M J Maeurer; S M Gollin; D Martin; W Swaney; J Bryant; C Castelli; P Robbins; G Parmiani; W J Storkus; M T Lotze
Journal:  J Clin Invest       Date:  1996-10-01       Impact factor: 14.808

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.